Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)

Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein, exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which increases nuclear retention of tumor suppressor proteins (TSPs), including p53, thereby limiting the translation of...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Hamid Ehsan, Myra Robinson, Peter M. Voorhees, Kristen Cassetta, Shanice Borden, Shebli Atrash, Manisha Bhutani, Cindy Varga, Mauricio Pineda-Roman, Reed Friend, Barry A. Paul
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2024-03-01
Schriftenreihe:	Life
Schlagworte:	Selinexor RRMM high-risk multiple myeloma
Online-Zugang:	https://www.mdpi.com/2075-1729/14/3/384
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!